Fulgent Genetics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fulgent Genetics Inc.
A relatively large outbreak in another major Chinese city after original epicenter Wuhan heightens the urgency for a more effective mRNA vaccine.
Medtech companies raised $2.4 billion in the fourth quarter, the second-strongest of the year; Q4 device M&A deals totaled $9 billion in value, led by Allergan's $2.9 billion buy of Acelity's LifeCell division. Diagnostics financings finished out the year at $721 million, an increase over the previous quarter and 2016's second-highest quarter, but diagnostics M&A activity was the lowest of the year at $87 million, with only two completed acquisitions.
Q3 saw a rise in the volume of initial public offerings, sparking hopes for a potential IPO rebound in 2016.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2016.
- Laboratory Testing Services
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- Fulgent Therapeutics LLC
- Fulgent Investment Development Limited
- Shenzhen Mingrui Consulting Co., Ltd.
- Fulgent Genetics Canada Inc.
- Shenzhen Fujin Gene Technology Co., Ltd.